Vical, Inc. (NASDAQ: VICL) announced Monday that top-line results from a Phase 3 trial of Allovectin, an investigational intratumoral cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE